PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.29
Dangerously higher D/E above 1.5x CRVO's 0.02. Jim Chanos would check for potential debt spiral risks.
1.49
Net debt 50-75% of CRVO's 1.73. Mohnish Pabrai would check if this competitive advantage in leverage translates to better reinvestment opportunities.
No Data
No Data available this quarter, please select a different quarter.
1.75
Current ratio below 50% of CRVO's 5.35. Jim Chanos would check for potential working capital crisis.
No Data
No Data available this quarter, please select a different quarter.